|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:naloxone
|
|
gptkbp:antidote
|
opioid toxicity
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:ATCCode
|
V03AB15
|
|
gptkbp:availableOn
|
community organizations
pharmacies
|
|
gptkbp:contraindication
|
hypersensitivity to naloxone
|
|
gptkbp:countryOfOperation
|
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:duration
|
30 to 90 minutes
|
|
gptkbp:firstAidUse
|
yes
|
|
gptkbp:form
|
nasal spray
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Narcan nasal spray
|
|
gptkbp:indication
|
opioid overdose
|
|
gptkbp:legalStatus
|
over-the-counter (United States)
|
|
gptkbp:manufacturer
|
gptkb:Emergent_BioSolutions
|
|
gptkbp:mechanismOfAction
|
opioid
|
|
gptkbp:onset
|
within minutes
|
|
gptkbp:packaging
|
single-use device
|
|
gptkbp:powers
|
4 mg per spray
|
|
gptkbp:pregnancyCategory
|
Category B (US)
|
|
gptkbp:prescriptionStatus
|
non-prescription (United States)
|
|
gptkbp:routeOfAdministration
|
intranasal
|
|
gptkbp:shelfLife
|
up to 3 years
|
|
gptkbp:sideEffect
|
headache
withdrawal symptoms
increased blood pressure
nasal discomfort
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:bfsParent
|
gptkb:Seamus_Mulligan
|
|
gptkbp:bfsLayer
|
7
|